Proteomic Characterization Identifies Clinically Relevant Subgroups of Gastrointestinal Stromal Tumors

Gastroenterology. 2024 Mar;166(3):450-465.e33. doi: 10.1053/j.gastro.2023.11.284. Epub 2023 Nov 22.

Abstract

Background & aims: Gastrointestinal stromal tumor (GIST) is the most common mesenchymal tumor of the gastrointestinal tract, and it has high metastatic and recurrence rates. We aimed to characterize the proteomic features of GIST to understand biological processes and treatment vulnerabilities.

Methods: Quantitative proteomics and phosphoproteomics analyses were performed on 193 patients with GIST to reveal the biological characteristics of GIST. Data-driven hypotheses were tested by performing functional experiments using both GIST cell lines and xenograft mouse models.

Results: Proteomic analysis revealed differences in the molecular features of GISTs from different locations or with different histological grades. MAPK7 was identified and functionally proved to be associated with tumor cell proliferation in GIST. Integrative analysis revealed that increased SQSTM1 expression inhibited the patient response to imatinib mesylate. Proteomics subtyping identified 4 clusters of tumors with different clinical and molecular attributes. Functional experiments confirmed the role of SRSF3 in promoting tumor cell proliferation and leading to poor prognosis.

Conclusions: Our study provides a valuable data resource and highlights potential therapeutic approaches for GIST.

Keywords: Gastrointestinal Stromal Tumor; Proteomic Subtypes; SRSF3.

MeSH terms

  • Animals
  • Antineoplastic Agents* / pharmacology
  • Antineoplastic Agents* / therapeutic use
  • Cell Line, Tumor
  • Disease Models, Animal
  • Gastrointestinal Neoplasms* / drug therapy
  • Gastrointestinal Neoplasms* / genetics
  • Gastrointestinal Stromal Tumors* / drug therapy
  • Gastrointestinal Stromal Tumors* / genetics
  • Humans
  • Imatinib Mesylate / pharmacology
  • Imatinib Mesylate / therapeutic use
  • Mice
  • Proteomics
  • Serine-Arginine Splicing Factors

Substances

  • Antineoplastic Agents
  • Imatinib Mesylate
  • SRSF3 protein, human
  • Serine-Arginine Splicing Factors